MARIETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
Craig-Hallum Capital Group 14th Annual Alpha Select Conference
Thursday, November 16, 2023
Sheraton New York Times Square Hotel
811 7th Avenue, W 53rd St
New York, NY
Mizuho Medical Device & Healthcare Services Summit 2023
Wednesday, December 6, 2023
Sofitel New York
45 W 44th St
New York, NY
Stifel MedTech 2023 Annual West Coast Bus Tour
Thursday, December 14, 2023
Four Seasons Palo Alto
2050 University Ave
East Palo Alto, CA
Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum, Mizuho, or Stifel representative.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$9.23 |
| Daily Change: | 0.17 1.88 |
| Daily Volume: | 109,935 |
| Market Cap: | US$1.360B |
October 30, 2024 October 01, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
